Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P06889 (Mol)
 630,302 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The H1-histamine receptor antagonist [3H]mepyramine bound with high affinity (Kd = 3-5 nM) to membranes derived from 1321N1 human astrocytoma cells. The H1-receptor antagonists triprolidine and diphenhydramine inhibited [3H]mepyramine binding with Kj values of 1-5 nM, whereas the Kj of the H2-histamine receptor antagonist cimetidine was greater than 100 microM. Histamine also inhibited [3H]mepyramine binding to 1321N1 cell membranes, and the histamine inhibition curve was shifted to the right and steepened in the presence of 1 microM guanosine 5'-O-(3-thiotriphosphate). Treatment of 1321N1 cells with pertussis toxin had no effect on the capacity of histamine to inhibit [3H]mepyramine binding either in the absence or presence of guanosine 5'-O-(3-thiotriphosphate). Therefore, agonist-occupied histamine receptors in these cells apparently interact with a guanine nucleotide regulatory protein that is not the inhibitory guanine nucleotide regulatory protein of adenylate cyclase. Although adenylate cyclase activity was not affected by histamine in a cell-free preparation, incubation of 1321N1 cells with histamine resulted in an attenuation of cyclic AMP accumulation. Analysis of cyclic AMP degradation in the presence of histamine indicated that the effects of histamine on cyclic AMP accumulation are mediated through activation of phosphodiesterase. This idea was supported by the fact that the phosphodiesterase inhibitor 1-isobutyl 3-methylxanthine blocked attenuation of cyclic AMP accumulation by histamine in a noncompetitive manner. Histamine also markedly increased phosphoinositide breakdown and 45Ca2+ efflux in 1321N1 cells. These histamine-induced effects apparently are mediated through H1-receptors, since triprolidine, but not cimetidine, potently inhibited histamine action. As for histamine interaction with its receptor, pertussis toxin had no effect on histamine-induced phosphoinositide breakdown, 45Ca2+ efflux, or attenuation of cyclic AMP accumulation. Taken together, these data indicate that 1321N1 human astrocytoma cells are a useful model system for the study of H1-histamine receptors and the biochemical responses mediated through these receptors.
Mol Pharmacol 1986 Feb
PMID:H1-histamine receptors on human astrocytoma cells. 241 44

Histamine induces dose-dependent increases in inositol-monophosphate, inositol-bisphosphate, and inositol-triphosphate in cultured human pulmonary artery and umbilical vein endothelial cells. Preincubation with isoproterenol results in synergistic potentiation of polyphosphoinositide breakdown. Isoproterenol does not change the effect of histamine, however, it does increase the potency of histamine in stimulating phosphoinositide turnover. This effect of isoproterenol is time-dependent reaching 350% at 120 min of preincubation. A synergistic potentiation of histamine-induced polyphosphoinositide breakdown by cyclic AMP stimulators has been observed after pretreatment of cultured endothelial cells with forskolin, dibutyryl cyclic AMP and cholera toxin. Our data suggest that isoproterenol potentiates histamine-induced polyphosphoinositide breakdown by operating via the adenylate cyclase system. This is the first evidence of synergistic potentiation of polyphosphoinositide breakdown by adenylate cyclase-coupled receptors in cultured human endothial cells.
J Mol Cell Cardiol 1989 Feb
PMID:Synergistic potentiation of polyphosphoinositide breakdown by adenylate cyclase coupled receptors in human endothelial cells. 254 24

Histamine stimulation of phosphoinositide breakdown has been studied in brain cortex from developing rats by measuring the accumulation of [3H]inositol monophosphate in lithium-treated slices prelabeled with [3H]inositol. Histamine stimulated phosphoinositide hydrolysis as early as day 3 after birth. The maximal response increased about 3-fold up to day 15 and remained essentially at the same level until adulthood. This developmental pattern contrasted with the 8-fold increase in [3H]mepyramine binding to histamine H1 receptors which takes place from the first to the end of the fourth week of life. Nonlinear regression analysis of concentration-effect curves for histamine generated at 6, 10, and 15 days of age revealed the presence of two components in the response, whereas a single component was found in adults. A high potency component showed EC50 values increasing from 6.4 microM at day 6 to 26.5 microM at day 15, and its contribution to the maximal response augmented from 65.8% to 78.9% during the same period. In 6-day-old animals, the H1 receptor agonists N alpha-methylhistamine and N alpha,N alpha-dimethylhistamine produced single-component responses with maximal effects similar to that estimated for the high potency component for histamine, and their relative potencies were consistent with an H1 receptor-mediated response. Inhibition constants for mepyramine, calculated from the parallel displacement of the concentration-response curves for N alpha-methylhistamine and the high potency component for histamine (6.3 nM and 10.8 nM, respectively) closely agreed with the reported affinity of rat brain H1 receptors for this compound. The low potency component of the response (EC50 = 175 microM at day 6 and EC50 = 260 microM at day 15) did not involve histamine-H2, serotonin 5-HT2, alpha 1-adrenergic, or muscarinic receptors. Pretreatment of 6-day-old cortical slices with the irreversible antagonist phenoxybenzamine, at concentrations that completely abolish [3H]mepyramine binding, left about 25% of the response to 1 mM histamine unaffected. This portion of the response, which was, moreover, insensitive to 1 microM mepyramine, was of a magnitude similar to that of the low potency component. Thus, at early stages of rat brain development, histamine induces phosphoinositide hydrolysis in part through a mechanism different from activation of H1 receptors. The loss of histamine potency and efficacy at H1 receptors throughout development is discussed and the natural occurrence of H1 receptor subsensitivity suggested.
Mol Pharmacol 1987 Sep
PMID:Histamine-stimulated phosphoinositide hydrolysis in developing rat brain. 282 91

Histamine, acting via H1 receptors, augments adenosine-induced cAMP accumulation in slices of guinea pig cerebral cortex by an indirect mechanism that appears to involve an intracellular messenger(s). To better characterize this process, the time course of this augmentation was examined in slices prelabeled with [3H] adenine. When histamine (1 mM) was added after the cAMP level had reached steady state with adenosine (0.1 mM), the cAMP level rose to a new steady level within 10 min (t 1/2, 2-3 min). There was no measurable delay in this response, indicating rapid activation of the augmentation after receptor occupation. Studies using the H1 receptor antagonist mepyramine indicated that the continued presence of the histamine stimulus was required to maintain the augmentation. Addition of mepyramine (10 microM) between 1 and 14 min after histamine caused cAMP levels to fall to a level similar to that obtained previously with adenosine alone, but with a delay of 2-3 min. This gives an upper estimate of the lifetime of any intracellular messenger involved in the augmentation process. To determine whether histamine acts by stimulating synthesis of cAMP or by inhibiting its breakdown, the fall in tissue cAMP content was studied after rapid removal of the adenosine stimulus by addition of adenosine deaminase. The initial fall was significantly faster in slices incubated with 0.1 mM adenosine plus 1 mM histamine than in slices with 0.1 mM adenosine alone, indicating increased synthesis and breakdown of cAMP in the presence of histamine. However, the higher breakdown rate probably reflects stimulation of the degradation process by the higher initial level of cAMP with histamine because, at equivalent levels, cAMP content fell at similar rates in both conditions. This was confirmed in other experiments in which similar steady state cAMP levels were achieved with and without histamine by appropriate choice of adenosine concentrations. It is therefore concluded that the direct effect of histamine is primarily to potentiate cAMP synthesis.
Mol Pharmacol 1988 Jun
PMID:Kinetic studies on the mechanism by which histamine H1 receptors potentiate cyclic AMP accumulation in guinea pig cerebral cortical slices. 283 36

In vitro and in vivo receptor-binding properties of the new serotonin antagonist, ritanserin, are reported. In in vitro binding assays, ritanserin shows high affinity binding to serotonin-S2 sites in rat frontal cortex tissue: IC50 = 0.9 nM without drug preincubation and 0.3 nM with 30-min drug preincubation; IC50 values for histamine-H1, dopamine-D2, and adrenergic-alpha 1 and -alpha 2 sites were 39-, 77-, 107-, and 166-fold higher, and at up to 1 microM, the drug did not bind to serotonin-S1 sites. In in vitro assays, ritanserin dissociated very slowly from serotonin-S2 (t1/2 = 160 min) and histamine-H1 sites (t1/2 = 77 min) and rapidly from dopamine-D2 sites (t1/2 = 11 min). Half-times of dissociation from adrenergic-alpha 1 and -alpha 2 sites were 18 and 26 min. The inhibition by ritanserin of [3H]ketanserin binding was found to be partially noncompetitive and the inhibitory potency increased with drug preincubation. Due to the slow dissociation of ritanserin from the serotonin-S2 sites, the drug cannot be displaced completely by [3H]ketanserin. In contrast, inhibition by ritanserin of [3H]haloperidol binding to dopamine-D2 sites in rat striatum was fully competitive, in agreement with the rapid dissociation of the drug from the latter sites. In ex vivo binding assays using brain areas of rats and guinea pigs treated subcutaneously with ritanserin, occupation of serotonin-S2 sites was observed at very low dosage (50% occupation at 0.08-0.1 mg/kg) and sites remained occupied during a prolonged time period (greater than 70% occupation up to 48 hr after 2.5 mg/kg ritanserin). Histamine-H1 receptor sites in guinea pig cerebellum became occupied at dosages 25-fold higher than the dosage producing occupation of frontal cortical serotonin-S2 sites. Dopamine-D2 sites in rat striatum and cortical adrenergic-alpha 1 sites became only slightly occupied (less than 20%) at higher dosages and the effect was not dose-dependent. Adrenergic-alpha 2 sites were not occupied up to doses of 160 mg/kg given subcutaneously. In vivo binding assays using [3H]spiperone confirmed the occupation of frontal cortical serotonin-S2 sites following low dosage of ritanserin and a minor occupation of striatal dopamine-D2 sites. Levels of dopamine and serotonin and their metabolites remained unchanged in brain areas of rats orally treated with ritanserin up to dosages of 40 mg/kg. At 160 mg/kg, there seemed to be a slight reduction in dopamine and serotonin content.(ABSTRACT TRUNCATED AT 400 WORDS)
Mol Pharmacol 1985 Jun
PMID:Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist. 286 May 58

Histamine metabolism, i.e., concentration of histamine and activities of histamine-degrading enzymes, histamine-N-methyltransferase (HMT), and diamine oxidase (DAO), were examined in the Arthus reaction induced in guinea pig skin. The specific activity of HMT was 44.12 +/- 3.80 pmole/min/mg protein and was about 15 times greater than that of DAO in control specimens. However, HMT activity decreased time dependently to 35% of the control at 3 hr and to 10% 48 hr after the initiation of the reaction. DAO activity increased to 150% till 1 hr followed by a linear decrease to 35% at 6 hr and to 10% at 48 hr. Histamine concentration showed a prominent linear decrease to 15% of the control at 2 hr followed by an increase to about 85% at 6 hr. This biphasic change seemed to be well explained by the dynamic changes in the activities of histamine-degrading enzymes. Such decrease in enzyme activities were not observed in other experimentally induced inflammations including dinitrochlorobenzene allergic and croton oil dermatitis. The addition of tissue extract from the Arthus reaction sites resulted in about 30% inhibition in both of two enzyme activities, suggesting the presence of some inhibitory factor(s) in the reaction sites.
Exp Mol Pathol 1986 Feb
PMID:Histamine metabolism in the Arthus reaction. 293 18

Phosphoinositide hydrolysis does not appear to desensitize in 1321N1 astrocytoma cells. The evidence for this is that 1) the rate of accumulation of [3H]inositol 1-phosphate is linear for up to 90 min in the presence of carbachol, 2) pretreatment of cells with 100 microM carbachol for 75 min does not diminish the subsequent ability of carbachol to increase [3H]inositol 1-phosphate accumulation, and 3) the production of all of the [3H]inositol phosphates including the polyphosphoinositide metabolites [3H]inositol bis- and trisphosphate continues for up to 75 min in the presence of carbachol and declines rapidly when the muscarinic receptor antagonist atropine is added. Only when cells are treated with carbachol for 2.5 hr or longer is there a reduction in carbachol-stimulated phosphoinositide hydrolysis, and this is associated with a decrease in muscarinic receptor number. There does appear to be desensitization of hormone-stimulated Ca2+ mobilization in 1321N1 cells, because treatment of these cells with carbachol for 75 min leads to loss of the subsequent ability of carbachol to stimulate unidirectional 45Ca2+ efflux. Histamine-stimulated 45Ca2+ efflux also is lost in cells pretreated with carbachol, indicating that the desensitization is heterologous. We conclude that desensitization of hormone-stimulated, unidirectional 45Ca2+ efflux cannot be accounted for by a loss of receptor-mediated phosphoinositide hydrolysis. If phosphoinositide hydrolysis or inositol triphosphate formation are signals for calcium mobilization, the site at which the calcium response desensitizes must be distal to the initial receptor-mediated activation of phospholipase C.
Mol Pharmacol 1985 Mar
PMID:Agonist-induced desensitization of muscarinic receptor-mediated calcium efflux without concomitant desensitization of phosphoinositide hydrolysis. 298 82

The protein phosphorylation changes associated with the contraction and relaxation of bovine carotid artery smooth muscle were studied using two-dimensional gel electrophoresis of labeled phosphoproteins. Muscle was stimulated with histamine, angiotensin II, 12-deoxyphorbol 13-isobutyrate (DPB) or high extracellular K+. Histamine induced a rapid and sustained contraction which was associated with an early (2 min) phosphorylation of 20 kDa myosin light chain (MLC) and two cytosolic proteins, Nos. 1 and 2, and with the late (60 min) phosphorylation of MLC, two isoelectric variants of desmin and ten other cytosolic proteins. Additionally, there was a decrease in the extent of phosphorylation of two cytosolic proteins, Nos. 9 and 10. Angiotensin II induced a rapid but transient contraction which was associated with the same early (2 min) phosphorylation changes, but with none of the late (60 min) changes. Elevation of the extracellular K+ concentration to 110 mM led to a sustained contraction which was associated with the phosphorylation of MLC and proteins Nos. 1 and 2 at both 2 and 60 min, but none of the other late phase phosphoproteins were seen. Addition of DPB, an activator of protein kinase C, induced a slowly developing but sustained contractile response which was associated with none of the early (5 min) phosphorylation changes. However, nearly all of late (60 min) protein phosphorylation changes were the same as those seen after histamine action. Addition of forskolin to either control or histamine-treated muscle led to an increase in the phosphorylation of three cytosolic proteins (Nos. 3, 8 and 13), and in the histamine-contracted muscle the dephosphorylation of MLC and proteins Nos. 4, 9, 10, 15 and 16. Similarly, forskolin induced a relaxation of DPB-treated muscle and the dephosphorylation of proteins Nos. 4, 9, 10, 15 and 16. These results suggest that there are two pathways by which histamine activates contraction: a Ca2+-calmodulin pathway which initiates the response, and a protein kinase C pathway which, along with the Ca2+-calmodulin pathway, sustains contraction.
Mol Cell Endocrinol 1988 Nov
PMID:Protein phosphorylation changes in bovine carotid artery smooth muscle during contraction and relaxation. 321 89

Histamine-N-methyltransferase, a major histamine-degrading enzyme in the skin, was purified from guinea pig skin about 150-fold. The enzymological characteristics including pH optimum, Km values for substrates, and molecular weight were almost consistent with those reported in the brain. Regulatory mechanism of the enzyme activity by biogenic amines was investigated using the purified specimen. Serotonin, tryptamine, and 5-methoxytryptamine intensely inhibited the activity while tryptophan, melatonin, N-acetylserotonin, tryptophol, and 5-hydroxyindole acetic acid had no significant effects. Dopamine, tyramine, 3-methyltyramine, and phenylethylamine also inhibited the activity while no particular effects were obtained by adrenaline, noradrenaline, tyrosine, and DOPA. Spermidine and cadaverine caused significant but weaker inhibition. These amines acted competitively with respect to histamine, although varying manners were observed with respect to S-adenosyl-L-methionine. From these results, it was concluded that the enzyme activity was inhibited by such compounds in which a certain chemical structure, CH2-CH2-NH2 group neighboring the hydrophobic group, was contained. A possible mechanism of inhibition by the amines is postulated, and possible roles of such compounds in the inflammation by impairing the histamine metabolism is discussed.
Exp Mol Pathol 1986 Dec
PMID:Regulation of the activity of histamine-N-methyltransferase from guinea pig skin by biogenic amines. 379 10

Antisera were raised in rabbits against histamine conjugated to human serum albumin (HSA) by the carbodiimide (ECDI) method. The specificity of the antisera was studied in a radioimmunoassay using 125I-protein A for detection of IgG binding. The HIS-HSA antisera reacted with histamine-HSA conjugates prepared by either the carbodiimide or diisocyanate coupling procedure, as well as with carbodiimide-prepared histamine-ferritin and histamine-ovalbumin conjugates. On the contrary, the antisera were unreactive with unconjugated HSA, ECDI-reacted HSA, or HSA conjugated to ethanolamine or pentylamine. Free unconjugated histamine significantly inhibited antibody binding to histamine-HSA and 50% inhibition of antibody binding (IC50) was recorded at 3 mM histamine concn. On a histamine molar concn basis a much lower inhibitory potency of free histamine was recorded, as compared to histamine-protein conjugates (IC50 = 3 X 10(-6) mM). This probably reflected amplification of antibody binding to the multivalent ligand, but possibly also that the protein carrier adds some common features to the antigenic determinant. Histidine, ornithine, glutamine, asparagine, sterylamine and several other amino acids lacked inhibitory effects. Histamine H1 and H2 receptor antagonists inhibited histamine binding to the histamine antibodies. The antagonists varied in their affinity for the histamine antibodies and 50% inhibition of antibody binding was recorded in the range of 1-50 mM concn of the antagonists. Comparing one H1 and one H2 antagonist (diphenhydramine and cimetidine, respectively) two of the sera were preferentially inhibited by cimetidine whereas the third serum seemed to be more prone to inhibition by diphenhydramine.
Mol Immunol 1986 Aug
PMID:Production and characterization of rabbit antibodies against histamine. 379 25


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>